311 related articles for article (PubMed ID: 26730568)
1. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
Calin R; Hamimi C; Lambert-Niclot S; Carcelain G; Bellet J; Assoumou L; Tubiana R; Calvez V; Dudoit Y; Costagliola D; Autran B; Katlama C;
AIDS; 2016 Mar; 30(5):761-9. PubMed ID: 26730568
[TBL] [Abstract][Full Text] [Related]
2. A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral control.
Assoumou L; Weiss L; Piketty C; Burgard M; Melard A; Girard PM; Rouzioux C; Costagliola D;
AIDS; 2015 Sep; 29(15):2003-7. PubMed ID: 26355572
[TBL] [Abstract][Full Text] [Related]
3. Rapid plasma viral suppression in naive HIV-infected patients with high CD4 cells and low viraemia initiating a dual nucleoside reverse transcriptase inhibitor strategy: a proof-of-concept study.
Seang S; Fourati S; Keita Y; Blanc C; Tubiana R; Schneider L; Valantin MA; Caby F; Calin R; Lambert-Niclot S; Marcelin AG; Calvez V; Costagliola D; Katlama C
J Antimicrob Chemother; 2014 Dec; 69(12):3356-9. PubMed ID: 25056835
[TBL] [Abstract][Full Text] [Related]
4. Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study).
Castagna A; Muccini C; Galli L; Bigoloni A; Poli A; Spagnuolo V; Nozza S; Racca S; Galli A; Cinque P; Carini E; Lazzarin A
J Antimicrob Chemother; 2019 Jul; 74(7):2039-2046. PubMed ID: 31225610
[TBL] [Abstract][Full Text] [Related]
5. Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
Ruiz L; Martinez-Picado J; Romeu J; Paredes R; Zayat MK; Marfil S; Negredo E; Sirera G; Tural C; Clotet B
AIDS; 2000 Mar; 14(4):397-403. PubMed ID: 10770542
[TBL] [Abstract][Full Text] [Related]
6. Virological remission after antiretroviral therapy interruption in female African HIV seroconverters.
Gossez M; Martin GE; Pace M; Ramjee G; Premraj A; Kaleebu P; Rees H; Inshaw J; Stöhr W; Meyerowitz J; Hopkins E; Jones M; Hurst J; Porter K; Babiker A; Fidler S; Frater J;
AIDS; 2019 Feb; 33(2):185-197. PubMed ID: 30325764
[TBL] [Abstract][Full Text] [Related]
7. Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.
Papasavvas E; Lada SM; Joseph J; Yin X; Liu Q; Azzoni L; Mounzer K; Kostman JR; Richman D; Montaner LJ
AIDS; 2018 Aug; 32(13):1763-1772. PubMed ID: 30045057
[TBL] [Abstract][Full Text] [Related]
8. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
9. DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus.
Thompson M; Heath SL; Sweeton B; Williams K; Cunningham P; Keele BF; Sen S; Palmer BE; Chomont N; Xu Y; Basu R; Hellerstein MS; Kwa S; Robinson HL
PLoS One; 2016; 11(10):e0163164. PubMed ID: 27711228
[TBL] [Abstract][Full Text] [Related]
10. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.
Li JZ; Etemad B; Ahmed H; Aga E; Bosch RJ; Mellors JW; Kuritzkes DR; Lederman MM; Para M; Gandhi RT
AIDS; 2016 Jan; 30(3):343-53. PubMed ID: 26588174
[TBL] [Abstract][Full Text] [Related]
11. Discordance between HIV-1 Population in Plasma at Rebound after Structured Treatment Interruption and Archived Provirus Population in Peripheral Blood Mononuclear Cells.
Hendricks CM; Cash MN; Tagliamonte MS; Riva A; Brander C; Llano A; Salemi M; Stevenson M; Mavian C
Microbiol Spectr; 2022 Aug; 10(4):e0135322. PubMed ID: 35699458
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y; Lacabaratz C; Lhomme E; Wiedemann A; Bauduin C; Fenwick C; Foucat E; Surenaud M; Guillaumat L; Boilet V; Rieux V; Bouchaud O; Girard PM; Molina JM; Morlat P; Hocqueloux L; Richert L; Pantaleo G; Lelièvre JD; Thiébaut R
J Virol; 2021 Apr; 95(9):. PubMed ID: 33568510
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 virological remission lasting more than 12 years after interruption of early antiretroviral therapy in a perinatally infected teenager enrolled in the French ANRS EPF-CO10 paediatric cohort: a case report.
Frange P; Faye A; Avettand-Fenoël V; Bellaton E; Descamps D; Angin M; David A; Caillat-Zucman S; Peytavin G; Dollfus C; Le Chenadec J; Warszawski J; Rouzioux C; Sáez-Cirión A;
Lancet HIV; 2016 Jan; 3(1):e49-54. PubMed ID: 26762993
[TBL] [Abstract][Full Text] [Related]
14. The gut mucosal viral reservoir in HIV-infected patients is not the major source of rebound plasma viremia following interruption of highly active antiretroviral therapy.
Lerner P; Guadalupe M; Donovan R; Hung J; Flamm J; Prindiville T; Sankaran-Walters S; Syvanen M; Wong JK; George MD; Dandekar S
J Virol; 2011 May; 85(10):4772-82. PubMed ID: 21345945
[TBL] [Abstract][Full Text] [Related]
15. A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir.
Piketty C; Weiss L; Assoumou L; Burgard M; Mélard A; Ragnaud JM; Bentata M; Girard PM; Rouzioux C; Costagliola D;
J Med Virol; 2010 Nov; 82(11):1819-28. PubMed ID: 20872707
[TBL] [Abstract][Full Text] [Related]
16. A higher CD4/CD8 ratio correlates with an ultralow cell-associated HIV-1 DNA level in chronically infected patients on antiretroviral therapy: a case control study.
Yue Y; Wang N; Han Y; Zhu T; Xie J; Qiu Z; Song X; Li Y; Routy JP; Wang J; Li T
BMC Infect Dis; 2017 Dec; 17(1):771. PubMed ID: 29246197
[TBL] [Abstract][Full Text] [Related]
17. Lack of correlation between the size of HIV proviral DNA reservoir and the level of immune activation in HIV-infected patients with a sustained undetectable HIV viral load for 10 years.
Poizot-Martin I; Faucher O; Obry-Roguet V; Nicolino-Brunet C; Ronot-Bregigeon S; Dignat-George F; Tamalet C
J Clin Virol; 2013 Aug; 57(4):351-5. PubMed ID: 23664725
[TBL] [Abstract][Full Text] [Related]
18. Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Dyrhol-Riise AM; Voltersvik P; Olofsson J; Asjö B
AIDS; 1999 Dec; 13(17):2365-76. PubMed ID: 10597778
[TBL] [Abstract][Full Text] [Related]
19. Quantification of HIV-DNA and residual viremia in patients starting ART by droplet digital PCR: Their dynamic decay and correlations with immunological parameters and virological success.
Alteri C; Scutari R; Stingone C; Maffongelli G; Brugneti M; Falasca F; Martini S; Bertoli A; Turriziani O; Sarmati L; Coppola N; Andreoni M; Santoro MM; Perno CF; Ceccherini-Silberstein F; Svicher V
J Clin Virol; 2019 Aug; 117():61-67. PubMed ID: 31229934
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 control after transient antiretroviral treatment initiated in primary infection: role of patient characteristics and effect of therapy.
Goujard C; Girault I; Rouzioux C; Lécuroux C; Deveau C; Chaix ML; Jacomet C; Talamali A; Delfraissy JF; Venet A; Meyer L; Sinet M;
Antivir Ther; 2012; 17(6):1001-9. PubMed ID: 22865544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
